Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | SARS-CoV-2 | Research article

Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metrics

Authors: Monia Makhoul, Farah Abou-Hijleh, Shaheen Seedat, Ghina R. Mumtaz, Hiam Chemaitelly, Houssein Ayoub, Laith J. Abu-Raddad

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Prospective observational data show that infected persons with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain polymerase chain reaction (PCR) positive for a prolonged duration, and that detectable antibodies develop slowly with time. We aimed to analyze how these effects can bias key epidemiological metrics used to track and monitor SARS-CoV-2 epidemics.

Methods

An age-structured mathematical model was constructed to simulate progression of SARS-CoV-2 epidemics in populations. PCR testing to diagnose infection and cross-sectional surveys to measure seroprevalence were also simulated. Analyses were conducted on simulated outcomes assuming a natural epidemic time course and an epidemic in presence of interventions.

Results

The prolonged PCR positivity biased the epidemiological measures. There was a lag of 10 days between the true epidemic peak and the actually-observed peak. Prior to epidemic peak, PCR positivity rate was twofold higher than that based only on current active infection, and half of those tested positive by PCR were in the prolonged PCR positivity stage after infection clearance. Post epidemic peak, PCR positivity rate poorly predicted true trend in active infection. Meanwhile, the prolonged PCR positivity did not appreciably bias estimation of the basic reproduction number R0. The time delay in development of detectable antibodies biased measured seroprevalence. The actually-observed seroprevalence substantially underestimated true prevalence of ever infection, with the underestimation being most pronounced around epidemic peak.

Conclusions

Caution is warranted in interpreting PCR and serological testing data, and any drawn inferences need to factor the effects of the investigated biases for an accurate assessment of epidemic dynamics.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–82.CrossRef Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–82.CrossRef
3.
go back to reference Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020;368(6490):489–93.CrossRef Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020;368(6490):489–93.CrossRef
4.
go back to reference Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–9.CrossRef Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–9.CrossRef
5.
go back to reference Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–1.CrossRef Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–1.CrossRef
6.
go back to reference He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–5.CrossRef He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–5.CrossRef
7.
go back to reference Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020;323:2249.CrossRef Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020;323:2249.CrossRef
8.
go back to reference Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, Mendu R, Jhang J, Arinsburg S, Gitman M, et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe. 2020;1(7):e283–9.CrossRef Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, Mendu R, Jhang J, Arinsburg S, Gitman M, et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe. 2020;1(7):e283–9.CrossRef
9.
go back to reference Ayoub HH, Chemaitelly H, Seedat S, Mumtaz GR, Makhoul M, Abu-Raddad LJ. Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide. PLoS ONE. 2020;15(8): e0237959.CrossRef Ayoub HH, Chemaitelly H, Seedat S, Mumtaz GR, Makhoul M, Abu-Raddad LJ. Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide. PLoS ONE. 2020;15(8): e0237959.CrossRef
10.
go back to reference Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. medRxiv. 2020:2020.2007.2016.20155317v20155312 (non-peer-reviewed preprint). Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. medRxiv. 2020:2020.2007.2016.20155317v20155312 (non-peer-reviewed preprint).
11.
go back to reference Ayoub HH, Chemaitelly H, Mumtaz GR, Seedat S, Awad SF, Makhoul M, Abu-Raddad LJ. Characterizing key attributes of the epidemiology of COVID-19 in China: model-based estimations. Global Epidemiology. 2020;2:100042.CrossRef Ayoub HH, Chemaitelly H, Mumtaz GR, Seedat S, Awad SF, Makhoul M, Abu-Raddad LJ. Characterizing key attributes of the epidemiology of COVID-19 in China: model-based estimations. Global Epidemiology. 2020;2:100042.CrossRef
12.
go back to reference Ayoub HH, Chemaitelly H, Seedat S, Makhoul M, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. medRxiv. 2020:2020.2011.2008.20184663 (non-peer-reviewed preprint). Ayoub HH, Chemaitelly H, Seedat S, Makhoul M, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. medRxiv. 2020:2020.2011.2008.20184663 (non-peer-reviewed preprint).
13.
go back to reference Makhoul M, Ayoub HH, Chemaitelly H, Seedat S, Mumtaz GR, Al-Omari S, Abu-Raddad LJ. Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. Vaccines. 2020;8(4):668.CrossRef Makhoul M, Ayoub HH, Chemaitelly H, Seedat S, Mumtaz GR, Al-Omari S, Abu-Raddad LJ. Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. Vaccines. 2020;8(4):668.CrossRef
14.
go back to reference He W, Yi GY, Zhu Y. Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and sensitivity analysis. J Med Virol. 2020;69:377. He W, Yi GY, Zhu Y. Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and sensitivity analysis. J Med Virol. 2020;69:377.
16.
go back to reference Nasrallah GK, Dargham SR, Shurrab F, Al-Sadeq DW, Al-Jighefee H, Chemaitelly H, Al Kanaani Z, Al Khal A, Al Kuwari E, Coyle P et al. Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting. medRxiv. 2020:2020.2012.2014.20248163. Nasrallah GK, Dargham SR, Shurrab F, Al-Sadeq DW, Al-Jighefee H, Chemaitelly H, Al Kanaani Z, Al Khal A, Al Kuwari E, Coyle P et al. Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting. medRxiv. 2020:2020.2012.2014.20248163.
17.
go back to reference Mallett S, Allen AJ, Graziadio S, Taylor SA, Sakai NS, Green K, Suklan J, Hyde C, Shinkins B, Zhelev Z et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. Bmc Med. 2020; 18(1). Mallett S, Allen AJ, Graziadio S, Taylor SA, Sakai NS, Green K, Suklan J, Hyde C, Shinkins B, Zhelev Z et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. Bmc Med. 2020; 18(1).
18.
go back to reference Guo L, Ren LL, Yang SY, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang YY, Wu C, Xiao Y, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;71(15):778–85.CrossRef Guo L, Ren LL, Yang SY, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang YY, Wu C, Xiao Y, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;71(15):778–85.CrossRef
Metadata
Title
Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metrics
Authors
Monia Makhoul
Farah Abou-Hijleh
Shaheen Seedat
Ghina R. Mumtaz
Hiam Chemaitelly
Houssein Ayoub
Laith J. Abu-Raddad
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07425-z

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.